Carbon Nanotubes under Scrutiny: Their Toxicity and Utility in Mesothelioma Research
Source abstract
Abstract
Research on the toxicity of engineered carbon nanotubes (CNT) was initiated by Belgian academic chemists and toxicologists more than 15 years ago. It is now undisputed that some of these attractive nanomaterials induce serious illness such as fibrosis and cancer. The physico-chemical determinants of CNT-induced adverse effects are now elucidated and include shape, nanoscale diameter, and structural defects. Generated in vitro and in vivo data on their inflammogenic and fibrogenic activities were combined and translated in AOP (adverse outcome pathways) available for risk assessment and regulatory policies. The asbestos-like carcinogenic effect of CNT, notably their capacity to induce malignant mesothelioma (MM), remain, however, a cause of concern for public health and strongly curb the craze for CNT in industries. MM still represents a real challenge for clinicians and a highly refractory cancer to existing therapeutic strategies. By comparing mesotheliomagenic CNT (needle-like CNT-N) to non mesotheliomagenic CNT (tangled-like CNT-T), our group generated a relevant animal model that highlights immune pathways specifically associated to the carcinogenic process. Evidence indicates that only CNT-N possess the intrinsic capacity to induce a preferential, rapid, and sustained accumulation of host immunosuppressive cells that subvert immune surveillance and suppress anti-mesothelioma immunity. This new concept offers novel horizons for the clinical management of mesothelioma and represents an additional tool for predicting the mesotheliomagenic activity of newly elaborated CNT or nanoparticles.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Occupational and environmental lung diseases · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Experimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
References (100+)
Show source-provided references
1. The smallest carbon nanotube10.1038/35040699 ↗
2. A formation mechanism for catalytically grown helix-shaped graphite nanotubes10.1126/science.265.5172.635 ↗
3. Simon, J., Flahaut, E., and Golzio, M. (2019). Overview of Carbon Nanotubes for Biomedical Applications. Materials, 12.10.3390/ma12040624 ↗
4. Biomedical applications of carbon nanomaterials: Drug and gene delivery potentials10.1002/jcp.26899 ↗
5. (2020, May 09). Available online: www.idtechex.com/fr/research-report/graphene-2d-materials-and-carbon-nanotubes-markets-technologies-and-opportunities-2018-2028/603; https://www.marketsandmarkets.com/Market-Reports/carbon-nanotubes-139; www.yanoresearch.com/en/press-release/show/press_id/2081-2019.
6. Low-Cost Catalyst Ink for Simple Patterning and Growth of High-Quality Single- and Double-Walled Carbon Nanotubes10.1021/acsami.9b19957 ↗
7. Modulating Ion Diffusivity and Electrode Conductivity of Carbon Nanotube@Mesoporous Carbon Fibers for High Performance Aluminum-Selenium Batteries10.1002/smll.201904310 ↗
8. Macroscopic Carbon Nanotube Structures for Lithium Batteries10.1002/smll.201902719 ↗
9. The Application of Carbon Nanotube/Graphene-Based Nanomaterials in Wastewater Treatment10.1002/smll.201902301 ↗
10. Carbon Nanomaterials for the Treatment of Heavy Metal-Contaminated Water and Environmental Remediation10.1186/s11671-019-3167-8 ↗
11. Use of iron mining tailings from dams for carbon nanotubes synthesis in fluidized bed for 17alpha-ethinylestradiol removal10.1016/j.envpol.2020.114099 ↗
12. Carbon Nanotube Assembly and Integration for Applications10.1186/s11671-019-3046-3 ↗
13. Carbon-Based Nanomaterials for Biomedical Applications: A Recent Study10.3389/fphar.2018.01401 ↗
14. Carbon-nanotube reinforcement of DNA-silica nanocomposites yields programmable and cell-instructive biocoatings10.1038/s41467-019-13381-1 ↗
15. Pei, B., Wang, W., Dunne, N., and Li, X. (2019). Applications of Carbon Nanotubes in Bone Tissue Regeneration and Engineering: Superiority, Concerns, Current Advancements, and Prospects. Nanomaterials, 9.10.3390/nano9101501 ↗
16. Induction of mesothelioma in p53+/− mouse by intraperitoneal application of multi-wall carbon nanotube10.2131/jts.33.105 ↗
17. Respiratory toxicity of multi-wall carbon nanotubes10.1016/j.taap.2005.01.008 ↗
18. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study10.1038/nnano.2008.111 ↗
19. Exposure to carbon nanotube material: Assessment of nanotube cytotoxicity using human keratinocyte cells10.1080/713853956 ↗
20. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation10.1093/toxsci/kfg243 ↗
21. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice10.1152/ajplung.00084.2005 ↗
22. Pulmonary toxicity of carbon nanotubes and asbestos—Similarities and differences10.1016/j.addr.2013.07.014 ↗
23. Mechanistic in vitro studies: What they have told us about carcinogenic properties of elongated mineral particles (EMPs)10.1016/j.taap.2018.07.018 ↗
24. Emerging Role of Immunosuppression in Diseases Induced by Micro- and Nano-Particles: Time to Revisit the Exclusive Inflammatory Scenario10.3389/fimmu.2018.02364 ↗
25. Innate immunity to inhaled particles: A new paradigm of collective recognition10.1016/j.cotox.2018.02.004 ↗
26. The puzzling issue of silica toxicity: Are silanols bridging the gaps between surface states and pathogenicity?10.1186/s12989-019-0315-3 ↗
27. The complex cascade of cellular events governing inflammasome activation and IL-1beta processing in response to inhaled particles10.1186/s12989-016-0150-8 ↗
28. The alarmin IL-1alpha is a master cytokine in acute lung inflammation induced by silica micro- and nanoparticles10.1186/s12989-014-0069-x ↗
29. Mechanisms of lung fibrosis induced by carbon nanotubes: Towards an Adverse Outcome Pathway (AOP)10.1186/s12989-016-0123-y ↗
30. CCR2(+) monocytic myeloid-derived suppressor cells (M-MDSCs) inhibit collagen degradation and promote lung fibrosis by producing transforming growth factor-beta110.1002/path.4956 ↗
31. Towards predicting the lung fibrogenic activity of MWCNT: Key role of endocytosis, kinase receptors and ERK 1/2 signaling10.3109/17435390.2015.1088588 ↗
32. Stat-6 signaling pathway and not Interleukin-1 mediates multi-walled carbon nanotube-induced lung fibrosis in mice: Insights from an adverse outcome pathway framework10.1186/s12989-017-0218-0 ↗
33. State of knowledge on the occupational exposure to carbon nanotubes10.1016/j.ijheh.2020.113472 ↗
34. Towards predicting the lung fibrogenic activity of nanomaterials: Experimental validation of an in vitro fibroblast proliferation assay10.1186/1743-8977-10-52 ↗
35. Thickness of multiwalled carbon nanotubes affects their lung toxicity10.1021/tx200255h ↗
36. Length-dependent pleural inflammation and parietal pleural responses after deposition of carbon nanotubes in the pulmonary airspaces of mice10.3109/17435390.2012.713527 ↗
37. Role of p53 in the chronic pulmonary immune response to tangled or rod-like multi-walled carbon nanotubes10.1080/17435390.2018.1502830 ↗
38. Structural defects play a major role in the acute lung toxicity of multiwall carbon nanotubes: Toxicological aspects10.1021/tx800101p ↗
39. Structural defects play a major role in the acute lung toxicity of multiwall carbon nanotubes: Physicochemical aspects10.1021/tx800100s ↗
40. An overview of existing mesothelioma registries worldwide, and the need for a US Registry10.1002/ajim.23069 ↗
41. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
42. The toxicology of chrysotile-containing brake debris: Implications for mesothelioma10.1080/10408444.2019.1568385 ↗
43. How asbestos and other fibers cause mesothelioma10.21037/tlcr.2020.02.01 ↗
44. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use10.21037/tlcr.2019.11.11 ↗
45. Diagnosis of Mesothelioma10.1016/j.path.2019.10.001 ↗
46. Malignant Mesothelioma: Has Anything Changed?10.1055/s-0039-1693406 ↗
47. Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?10.3389/fonc.2020.00343 ↗
48. Chemotherapy options versus “novel” therapies: How should we treat patients with malignant pleural mesothelioma10.21037/tlcr.2020.01.16 ↗
49. Integration of inflammation, fibrosis, and cancer induced by carbon nanotubes10.1080/17435390.2019.1651920 ↗
50. Carbon Nanotubes and Other Engineered Nanoparticles Induced Pathophysiology on Mesothelial Cells and Mesothelial Membranes10.3389/fphys.2018.00295 ↗
51. Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes10.1016/S1470-2045(14)71109-X ↗
52. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2017). Some Nanomaterials and Some Fibres, International Agency for Research on Cancer. PMID: 31829532.
53. The asbestos-carbon nanotube analogy: An update10.1016/j.taap.2018.06.027 ↗
54. The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models10.3389/fonc.2020.00388 ↗
55. Malignant mesothelioma as an oxidative stress-induced cancer: An update10.1016/j.freeradbiomed.2015.05.002 ↗
56. Asbestos, carbon nanotubes and the pleural mesothelium: A review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma10.1186/1743-8977-7-5 ↗
57. Weight of evidence analysis for assessing the genotoxic potential of carbon nanotubes10.1080/10408444.2017.1367755 ↗
58. Reactive oxygen species a double-edged sword for mesothelioma10.18632/oncotarget.4253 ↗
59. Mitsui-7, heat-treated, and nitrogen-doped multi-walled carbon nanotubes elicit genotoxicity in human lung epithelial cells10.1186/s12989-019-0318-0 ↗
60. Multi-walled carbon nanotubes upregulate mitochondrial gene expression and trigger mitochondrial dysfunction in primary human bronchial epithelial cells10.1080/17435390.2019.1655107 ↗
61. Differences in MWCNT- and SWCNT-induced DNA methylation alterations in association with the nuclear deposition10.1186/s12989-018-0244-6 ↗
62. Carbon Nanotube- and Asbestos-Induced DNA and RNA Methylation Changes in Bronchial Epithelial Cells10.1021/acs.chemrestox.8b00406 ↗
63. Induction and recovery of CpG site specific methylation changes in human bronchial cells after long-term exposure to carbon nanotubes and asbestos10.1016/j.envint.2020.105530 ↗
64. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas10.1016/j.ajpath.2012.12.028 ↗
65. In vitro chromosomal aberrations induced by various shapes of multi-walled carbon nanotubes (MWCNTs)10.1539/joh.16-0099-OA ↗
66. Inflammation in malignant mesothelioma—Friend or foe?
67. CREB-induced inflammation is important for malignant mesothelioma growth10.1016/j.ajpath.2014.06.008 ↗
68. Preclinical Models of Malignant Mesothelioma10.3389/fonc.2020.00101 ↗
69. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation10.1038/nnano.2010.44 ↗
70. The role of interleukin-6 in malignant mesothelioma
71. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis10.1073/pnas.0604008103 ↗
72. Kishimoto, T., Fujimoto, N., Ebara, T., Omori, T., Oguri, T., Niimi, A., Yokoyama, T., Kato, M., Usami, I., and Nishio, M. (2019). Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients. BMC Cancer, 19.10.1186/s12885-019-6419-1 ↗
73. The Current Understanding of Asbestos-Induced Epigenetic Changes Associated with Lung Cancer
74. Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells10.1007/s00408-015-9744-4 ↗
75. Mesothelioma: Recent highlights10.21037/atm.2017.04.29 ↗
76. BAP1 regulates different mechanisms of cell death10.1038/s41419-018-1206-5 ↗
77. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy10.1158/2326-6066.CIR-16-0309 ↗
78. Antiangiogeneic Strategies in Mesothelioma10.3389/fonc.2020.00126 ↗
79. The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy10.3389/fonc.2019.01366 ↗
80. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes10.1172/jci.insight.89014 ↗
81. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects10.1165/rcmb.2013-0472TR ↗
82. Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions10.1016/j.jtho.2016.07.019 ↗
83. Low-dose cyclophosphamide depletes circulating naive and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy10.1080/2162402X.2018.1474318 ↗
84. Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes10.1080/2162402X.2019.1638211 ↗
85. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma10.1016/j.jtho.2019.03.029 ↗
86. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity10.1084/jem.20171440 ↗
87. Tumor-associated macrophages in thoracic malignancies10.1016/j.lungcan.2013.02.017 ↗
88. Use of Immune Checkpoint Inhibitors in Mesothelioma10.1007/s11864-019-0613-x ↗
89. Remon, J., Passiglia, F., Ahn, M.J., Barlesi, F., Forde, P.M., Garon, E.B., Gettinger, S., Goldberg, S.B., Herbst, R.S., and Horn, L. (2020). Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J. Thorac. Oncol.10.1016/j.jtho.2020.03.006 ↗
90. Immunotherapy in Malignant Pleural Mesothelioma10.3389/fonc.2020.00187 ↗
91. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma10.1038/sj.bjc.6605814 ↗
92. Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells10.1186/s12989-016-0158-0 ↗
93. MDSC and TGFbeta Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes10.1158/0008-5472.CAN-14-2376 ↗
94. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells10.1002/smll.201201470 ↗
95. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes10.1093/toxsci/kfm196 ↗
96. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice10.1038/nnano.2009.151 ↗
97. Pro-inflammatory and potential allergic responses resulting from B cell activation in mice treated with multi-walled carbon nanotubes by intratracheal instillation10.1016/j.tox.2009.02.009 ↗
98. Park, E.J., Roh, J., Kim, S.N., Kang, M.S., Lee, B.S., Kim, Y., and Choi, S. (2011). Biological toxicity and inflammatory response of semi-single-walled carbon nanotubes. PLoS ONE, 6.10.1371/journal.pone.0025892 ↗
99. A single intratracheal instillation of single-walled carbon nanotubes induced early lung fibrosis and subchronic tissue damage in mice10.1007/s00204-011-0655-8 ↗
100. The increases in relative mRNA expressions of inflammatory cytokines and chemokines in splenic macrophages from rats exposed to multi-walled carbon nanotubes by whole-body inhalation for 13 weeks10.3109/08958378.2014.953275 ↗